Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apramycin is a structurally unique aminoglycoside antibiotic produced by *Streptomyces tenebrarius* and primarily used in veterinary medicine[4][5]. It exhibits bactericidal activity against a broad range of gram-negative bacteria, including *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*[4][5]. The drug acts by binding to the bacterial 30S ribosomal subunit (specifically the 16S rRNA), causing misreading of mRNA and inhibiting protein synthesis, which leads to both errors in translation and reduced efficiency of protein production[4][5][7]. This dual mechanism underlies its potent bactericidal effect. While widely approved for use in animals (cattle, pigs, chickens) for gastrointestinal infections such as colibacillosis and salmonellosis, apramycin is not approved for human use[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on apramycin.